Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Glucagon - Xeris Pharmaceuticals

Next Previous
Drug Profile

Glucagon - Xeris Pharmaceuticals

Alternative Names: G-Pen; G-Pen Jr; G-Pen Mini; Glucagon infusion - Xeris; Glucagon RTU; Gvoke HypoPen; Gvoke PFS; Gvoke RTU Micro™; Gvoke® Kit; Injectable stable glucagon - Xeris; Ogluo; Ready-to-use glucagon; Xeris glucagon; XeriSol G-Pump; XP-9164

Latest Information Update: 28 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator XERIS Pharmaceuticals
  • Developer Tetris Pharma; Xeris Pharmaceuticals
  • Class Antihypoglycaemics; Pancreatic hormones
  • Mechanism of Action Glucagon receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypoglycaemia
  • New Molecular Entity No
  • Available For Licensing Yes - Hypoglycaemia

Highest Development Phases

  • Marketed Hypoglycaemia
  • No development reported Gastrointestinal disorders

Most Recent Events

  • 28 Jan 2024 No recent reports of development identified for phase-I development in Gastrointestinal-disorders in USA (Parenteral)
  • 20 Jul 2023 Xeris Pharmaceuticals plans to launch glucagon prefilled autoinjector pen (Ogluo®) for Hypoglycaemia in other key territories by second half of 2023
  • 01 May 2023 Launched for Hypoglycaemia (In adolescents, In children, In adults) in Norway, Austria, Denmark (SC)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top